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Abstract
Niemann-Pick disease type C (NP-C) is a rare, progressive, irreversible disease leading to disabling neurological
manifestations and premature death. The estimated disease incidence is 1:120,000 live births, but this likely
represents an underestimate, as the disease may be under-diagnosed due to its highly heterogeneous presentation.
NP-C is characterised by visceral, neurological and psychiatric manifestations that are not specific to the disease and
that can be found in other conditions. The aim of this review is to provide non-specialists with an expert-based,
detailed description of NP-C signs and symptoms, including how they present in patients and how they can be
assessed. Early disease detection should rely on seeking a combination of signs and symptoms, rather than isolated
findings. Examples of combinations which are strongly suggestive of NP-C include: splenomegaly and vertical
supranuclear gaze palsy (VSGP); splenomegaly and clumsiness; splenomegaly and schizophrenia-like psychosis;
psychotic symptoms and cognitive decline; and ataxia with dystonia, dysarthria/dysphagia and cognitive decline.
VSGP is a hallmark of NP-C and becomes highly specific of the disease when it occurs in combination with other
manifestations (e.g. splenomegaly, ataxia). In young infants (<2 years), abnormal saccades may first manifest as
slowing and shortening of upward saccades, long before gaze palsy onset. While visceral manifestations tend to
predominate during the perinatal and infantile period (2 months–6 years of age), neurological and psychiatric
involvement is more prominent during the juvenile/adult period (>6 years of age). Psychosis in NP-C is atypical
and variably responsive to treatment. Progressive cognitive decline, which always occurs in patients with NP-C,
manifests as memory and executive impairment in juvenile/adult patients. Disease prognosis mainly correlates
with the age at onset of the neurological signs, with early-onset forms progressing faster. Therefore, a detailed and
descriptive picture of NP-C signs and symptoms may help improve disease detection and early diagnosis, so that
therapy with miglustat (ZavescaW), the only available treatment approved to date, can be started as soon as
neurological symptoms appear, in order to slow disease progression.
Keywords: Niemann-Pick disease type C, Lysosomal lipid storage disease, Splenomegaly, Ataxia, Dystonia, Vertical
supranuclear gaze palsy, Gelastic cataplexy, Cognitive impairment, Diagnosis
Introduction
Niemann-Pick disease type C (NP-C) is a rare, progres-
sive genetic lysosomal lipid storage disease caused by
mutations in the NPC1 or NPC2 gene [1,2]. It is a highly
heterogeneous disease, characterised by visceral, neuro-
logical and psychiatric manifestations that can present
alone, or in specific or non-specific combinations. More-
over, age at onset and disease course vary greatly from
one patient to another, including among siblings [1,2].
Patients often first present to general practitioners; due to
its challenging presentation, especially for non-specialists,
the disease often remains undetected for many years,
with an average delay in diagnosis of 5–6 years from
onset of neurological symptoms [3-6]). Early diagnosis
is essential so that therapy with miglustat (ZavescaW,
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland),
the only available disease-specific therapy approved for
NP-C [7], can be initiated as soon as neurological
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symptoms appear in order to slow the progression of
neurological damage.
Individual NP-C manifestations are not specific to the
disease, but the combination of multiple signs and symp-
toms shows more diagnostic specificity for NP-C, which
may aid with disease detection. Therefore, understanding
how and in which combination these manifestations
present in the context of NP-C may help physicians identify
possible suspected cases of NP-C.
This review provides an expert-based descriptive clinical
picture of NP-C that goes beyond the scope of currently
available information to practising clinicians, and includes
details on specific signs and symptoms and how they
present in individuals with NP-C. This qualitative de-
scription of NP-C signs and symptoms is not limited to
published clinical study data, but also reflects experts’
opinion drawn from clinical practice and personal ex-
perience. It aims to increase disease awareness among
physicians in order to improve early diagnosis and
timely referral to specialists of patients with suspected
disease.
Disease description, epidemiology and aetiology
NP-C is a genetic, progressive, irreversible and chronically
debilitating neurovisceral lysosomal lipid storage disease
leading to premature death [1,2]. NP-C is generally
panethnic, although some mutations may occur with
higher incidence in defined ethnic groups [8,9]. The
minimal estimated incidence of the disease is one case
in every 120,000 live births [2], although this value is
likely to represent an underestimation due to failure to
reliably recognise the disease (see below).
NP-C is a genetic autosomal recessive disease caused
by mutations in the genes NPC1 (~95% of cases), NPC2
(~4% of cases) and possibly other as yet unidentified
genes (~1% of cases) [1,10,11]. As of November 2012,
252 gene sequence variants have been listed for NPC1
and 18 for NPC2, with a majority of point mutations
[12]. Mutations in either gene lead to the same cellular
deficits, including impaired cholesterol esterification [13]
and intracellular lipid trafficking [14]. This results in
intracellular accumulation of different lipids and altered
sphingolipid metabolism leading to the pathophysiology
of the disease. Putative functions of NPC1 and NPC2
and their role in the pathophysiology of NP-C have been
described more comprehensively elsewhere [2,14,15].
Depending on whether the NPC1 or NPC2 gene carries
mutations, the disease is sometimes referred to as
NP-C1 or NP-C2, respectively. For certain gene mutations,
there appears to be a correlation between genotype and
the severity of the neurological course of the disease [16].
For a comprehensive definition of the disease, including
its historical delineation, we refer the reader to a recent
review [2].
Clinical description and differential diagnosis
NP-C is a complex disease that first of all affects the
spleen, liver and brain, resulting in visceral abnormalities
as well as neurological and psychiatric manifestations
(Table 1). The combined presentation of visceral, neuro-
logical and psychiatric manifestations should therefore
lead to the consideration of NP-C in the differential
diagnosis of this symptomatology. Examples of combi-
nations which are strongly suggestive of NP-C include:
splenomegaly and vertical supranuclear gaze palsy (VSGP);
splenomegaly and clumsiness; splenomegaly and schizo-
phrenia-like psychosis; psychotic symptoms and cognitive
decline; and ataxia with dystonia, dysarthria/dysphagia and
cognitive decline [17] (Table 2).
The combination of cerebellar ataxia and dystonia of
the hands and the face is one motor hallmark of NP-C.
However, a combination of cerebellar ataxia and dystonia
can also be found in other diseases, including mito-
chondrial disorders such as Leigh syndrome, GM2
gangliosidosis, ataxia with oculomotor apraxia type I,
Gaucher disease type 3 (GD3), and spinocerebellar ataxia.
Table 1 Classification of signs and symptoms in NP-C
Visceral
Isolated unexplained splenomegaly
Hepatomegaly/Splenomegaly
Prolonged neonatal cholestatic jaundice
Hydrops foetalis or foetal ascites
Pneumopathologies (aspiration pneumonia,
alveolar lipidosis, interstitial lung involvement)
Mild thrombocytopenia
Neurological
Vertical supranuclear gaze palsy
Gelastic cataplexy
Ataxia
Dystonia
Dysarthria
Dysphagia
Hypotonia
Clumsiness
Delayed developmental milestones
Seizures
Hearing loss
Psychiatric
Developmental delay and pre-senile cognitive decline
Organic psychosis
Disruptive/aggressive behaviour
Progressive development of
treatment-resistant psychiatric symptoms
Abbreviation: NP-C, Niemann-Pick disease type C.
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Therefore, even if this combination is highly suggestive of
NP-C, it does not necessarily confirm a diagnosis of NP-C.
NP-C presentations are often categorised based on the
age at onset of the neurological symptoms: early-infantile
(2 months–2 years of age), late-infantile (2–6 years of age),
juvenile (6–12 years of age), adolescent/adult (>12 years
of age). The perinatal form (up to the age of 2 months) is
characterised by systemic symptoms only [1,2].
Visceral symptoms in NP-C
Isolated unexplained splenomegaly with or without
hepatomegaly
Historical or current isolated unexplained splenomegaly,
with or without hepatomegaly, is observed in the majority
of patients with NP-C [1] and is the strongest visceral
indicator of the disease [18]. When present in combination
with other neurological and/or psychiatric symptoms,
including VSGP, ataxia and schizophrenia-like symptoms,
isolated splenomegaly becomes highly suggestive of NP-C
[1]. Isolated unexplained splenomegaly should always lead
to the inclusion of NP-C in the differential diagnosis, and
hence trigger a search for other symptoms of the disease.
Splenomegaly in NP-C presents along a continuum,
ranging from slight to tremendous enlargement, even in
young children. Importantly, the degree of splenomegaly
does not correlate with neurological manifestations,
disease severity or illness stage. Absence of splenomegaly
should not lead to the exclusion of NP-C.
In young patients, splenomegaly can be assessed by
turning the patient on the right side in order to have the
spleen falling downwards. In this position, the spleen
should not be palpable under normal conditions. A palp-
able spleen indicates that its size is increased by at least
two-fold. In adolescent and adult patients, mild spleno-
megaly may only be detected by abdominal imaging such
as ultrasound [1,3].
Unlike splenomegaly, hepatomegaly is less frequently
observed in adult patients with NP-C [1,3]. Hepatomegaly
presentation in NP-C is non-specific; it generally appears
at the same age as splenomegaly, or in some cases may
present without it, which is often attributed to a failure
to clinically detect splenomegaly in the absence of an
abdominal ultrasound. Hepatomegaly can be detected
by palpation of the patient lying in a supine position,
starting from the right flank and slowly moving upwards.
A palpable lower edge of the liver indicates hepatomegaly.
Upward palpation should also be started from the left
flank, as occasionally only the left lobe of the liver is
enlarged, crossing over the midline. While up to a two-
fold increase in spleen size can remain impalpable, liver
enlargement as small as 1 cm can be readily felt. Notably,
the degree of hepatomegaly and splenomegaly are not
related, and unlike splenomegaly [2], hepatomegaly does
not appear to resolve spontaneously.
Isolated spleno- or hepatosplenomegaly also occur in
some other inherited metabolic diseases, such as mucopoly-
saccharidoses, glycogen storage disorders, Sandhoff disease,
GD3, lysosomal acid lipase deficiency and Niemann-Pick
disease type A and B [1].
Prolonged or unexplained neonatal cholestatic jaundice
Signs of perinatal liver involvement range from transient
conjugated hyperbilirubinaemia to severe cholestatic hepa-
topathy leading to liver failure and death in the first year
of life.
A history of prolonged or unexplained neonatal chole-
static jaundice is a strong visceral indicator of NP-C [18].
Generally defined as prolonged conjugated hyperbilirubi-
naemia that occurs in newborns, it is frequently observed in
patients with early- and late-infantile disease onset [19-22].
In NP-C, jaundice always has a cholestatic origin and is
defined by a conjugated bilirubin level >1.2 mg/dL and/
or >30% of total bilirubin for a period of over 2 weeks [1].
Conjugated bilirubin levels and speed of symptom
resolution are non-specific in NP-C. Acholic stools can be
a characteristic of NP-C-related cholestatic jaundice.
Since this condition does not require phototherapy (unlike
unconjugated jaundice), its symptoms may often not be
recalled by parents and hence may be missed when
obtaining medical history.
Cholestasis should always lead to the consideration of
NP-C in the differential diagnosis of neonatal jaundice. In
neonates and young infants, NP-C should be differentiated
from other causes of cholestatic jaundice, e.g. idiopathic
neonatal hepatitis or biliary atresia [1]. The occurrence of
isolated spleno- or hepatosplenomegaly is a helpful indica-
tor and should raise suspicion of NP-C [18].
Hydrops foetalis or sibling with foetal ascites
The presence of perinatal hydrops foetalis or a sibling
with foetal ascites occurs frequently in newborns with
lysosomal storage diseases [23,24]. However, they are
Table 2 Sign and symptom combinations strongly
suggestive of NP-C
Splenomegaly +
Vertical supranuclear gaze palsy
Hypotonia
Schizophrenia-like psychosis
Gelastic cataplexia
Delayed developmental milestones
Ataxia +
Dystonia
Dysarthria/dysphagia
Cognitive decline
Psychotic symptoms + Cognitive decline
The combination of one of the symptoms on the left with at least one of
those on the right is strongly suggestive of NP-C.
Abbreviation: NP-C, Niemann-Pick disease type C.
Mengel et al. Orphanet Journal of Rare Diseases 2013, 8:166 Page 3 of 11
http://www.ojrd.com/content/8/1/166
considered ancillary indicators of NP-C as they are less
frequent in patients with this disease [18,20,25]. In NP-C,
hydrops foetalis has a non-immune origin and always
presents with ascites, never as a classical hydrops foetalis.
It is usually detected upon antenatal foetal ultrasonog-
raphy scanning and presents as global swelling, with some
fluid accumulating in the abdominal cavity or around the
heart. Hydrops foetalis may be missed during the medical
and family history, because the information is often held
with obstetricians rather than paediatricians. Differential
diagnosis for hydrops foetalis include chromosomal disor-
ders, congenital heart malformations, infectious diseases
and haemoglobin disorders.
Other symptomatology
Lung disease can occur in both NP-C1 and NP-C2
disease, and is usually associated with more severe
types of the disease. In NP-C2, the clinical picture can
be similar to that of chronic lung disease of the newborn
in the absence of a history to support it. Helical computed
tomography imaging of the chest may occasionally show
classical interstitial lung disease. These features have
been poorly described in the literature [26-28] but are
often anecdotally reported by experts. There is no specific
therapy for the pulmonary manifestations, although bone
marrow transplantation may offer some resolution in
NP-C2 [29].
Mild thrombocytopenia in newborns or toddlers with
NP-C has been anecdotally reported, with limited evidence
([1] and CJH, personal communication). This finding is
non-specific, as platelet abnormalities are common in
cases of splenomegaly and have been described in other
lysosomal storage diseases. Bone marrow infiltration
with foam cells may cause platelet abnormalities in
newborns, although this remains to be confirmed. Foamy
cells can be detected by bone marrow aspiration. Usually,
patients with classical foamy cells are the most severely
affected and present with large splenomegaly, low platelet
counts, bone infiltrates, and a most widespread presenta-
tion. It should be noted, however, that patients may rarely
present with classical foamy cells and splenomegaly from
an early age, yet remain asymptomatic for the neurological
manifestations of the disease.
Neurological symptoms in NP-C
Vertical supranuclear gaze palsy
VSGP is characterised by impaired saccadic movements
of the eyes in the vertical direction as a result of a
supranuclear lesion [30]. Patients with VSGP exhibit a
deficit in voluntary and reflexive vertical saccades, as
well as in vestibulo-ocular nystagmus. Along with gelastic
cataplexy, VSGP is the strongest neurological indicator of
NP-C [18], and becomes highly predictive of NP-C when
found in combination with other manifestations, such as
splenomegaly, ataxia or psychosis. During later stages of
the disease, horizontal saccades are also affected, reflecting
progressive degeneration of neurons within the paramed-
ian pontine reticular formation, which controls horizontal
saccades [30-32]. Neuronal loss in the rostral interstitial
nuclei of the medial longitudinal fasciculus results in a
palsy of voluntary and reflexive vertical saccades, as
well as of the quick phases of vertical nystagmus [1,30].
Importantly, the vestibulo-ocular reflex, which depends
on the vestibular nuclei under the control of cerebellar
projections, is often preserved until very late in the
disease progression [1,3,32,33]. Slow and hypometric
vertical saccades followed by compensating head move-
ment may be the first sign in children and infants long
before gaze palsy develops, and may start in infants
below the age of 2 years. Children may fall as they
become unable to adjust their vision for stairs or other
obstacles. In cases where children are clumsy and fall often,
but have not been diagnosed with VSGP, the initiation,
velocity and amplitude of upward saccades should be
assessed. Typically, children close their eyes when trying
to look up and re-open them once they have reached their
upward position; alternatively, they may blink when asked
to look up. These are features that a physician should pay
attention to when conducting a clinical examination. In
older children, adolescents and adults, downward gaze
appears to be affected first [3,30]; it can manifest as a
tilt of the head for everyday tasks such as writing, driving,
or using a cash machine, or as a difficulty when descending
stairs [3].
During the neurological examination, it is important
to assess voluntary vertical saccades, and not only eye
pursuit movements (Figure 1) [30]. The examiner should
require the subject to visually fixate on two separate
objects, e.g. the examiner’s finger and a hatpin, which
are displaced first horizontally and then vertically, but
always within the subject’s visual field. The subject is
then asked to look at each object alternately.
VSGP can be misdiagnosed as vertical ocular motor
apraxia (OMA), both of which involve impaired vertical
saccades. The two can be differentiated by assessing
reflexive saccades, which are abnormal in VSGP but more
promptly generated in OMA [30]. In addition, VSGP
involves reduced saccadic velocity and range, whereas
vertical OMA is typically characterised by a deficit in
the initiation of voluntary vertical saccades, with normal
vertical quick phases of nystagmus [30]. Reflexive saccades
can be assessed by asking the patient to look at the ex-
aminer’s wiggling finger, which suddenly moves above
or below the straight ahead position of the patient [30].
In children, OMA usually occurs in the horizontal
plane; therefore, abnormal initiation and speed of verti-
cal saccades makes OMA less likely and favours a
VSGP diagnosis.
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Other diseases and conditions associated with VSGP
include, for example, progressive supranuclear palsy or
other tauopathies, multiple system atrophy, dementia
with Lewy bodies, spinocerebellar ataxia, Tay-Sachs dis-
ease, Wilson disease, vitamin B12 deficiency, Wernicke
encephalopathy, Huntington’s disease and Creutzfeldt–
Jakob disease [30]. As opposed to these disorders,
VSGP development has an earlier onset in NP-C.
Ataxia
Ataxia, which is associated with early loss of Purkinje
cells in the cerebellum [34,35], is a moderate indicator of
NP-C [18]. In combination with dystonic manifestations
of the hands and the face it becomes highly suggestive
of NP-C.
In NP-C, ataxia presents as ‘slow’ ataxia, manifesting
itself in quite slow movements, compared with other
ataxic patients. Gait may appear normal in the early stages
of the disease. Children with a mild form of NP-C may
appear to be slow, for example, walking instead of running,
or cautiously taking objects instead of rapidly grabbing
them. Ataxia generally appears after dystonia, with the
delay between the two symptoms dependent on disease
progression, however, in a proportion of infantile and
juvenile-onset cases, ataxia may present before dystonia is
apparent. In cases where ataxia is the only presenting
neurological symptom, it may be useful to wait and watch
for additional signs before suspecting NP-C, as ataxia can
have multiple aetiologies.
Clinical assessment of ataxia includes provocative tests,
such as tandem gait, rapidly alternating movements,
finger-to-nose or heel-to-shin tests. Patients with NP-C
may be able to adequately perform these tests, but will
exhibit slower movements to compensate for their ataxia.
Ataxia can be further assessed based on standard scales,
such as the International Cooperative Ataxia Rating Scale
[36] and the Brief Ataxia Rating Scale [37], which may be
more useful in the office setting.
NP-C is part of the expanding group of hereditary
autosomal recessive cerebellar ataxias (ARCAs) [38]. How-
ever, the following aspects may help distinguish NP-C from
other ARCAs: absence of retinal/macular degeneration;
lack of peripheral neuropathy in adult patients; marked
cerebellar atrophy is usually only observed in advanced
stages of the disease; and the presence of VSGP, an almost
constant feature which, in combination with splenomegaly,
virtually defines the clinical diagnosis of NP-C.
Gelastic cataplexy
Gelastic cataplexy, characterised by episodes of sudden
loss of muscle tone that can cause the patient to collapse
or fall, is one of the strongest neurological indicators
of NP-C [18]. Although relatively rare, it is a strong
predictor of NP-C when it occurs in combination with
other manifestations, such as VSGP. Gelastic cataplexy
is not associated with loss of consciousness, abnormal
vigilance or altered awareness. In NP-C, gelastic cata-
plexy presents along a continuum, from rubbery feel-
ing in the legs and minor head-drops to full collapse
of the entire body [1], and can appear as early as
2 years of age.
Figure 1 Clinical assessment of vertical supranuclear gaze palsy. During the neurological evaluation of eye movements, assessing eye
pursuit movements alone (left) is insufficient: voluntary saccades must be tested (right). The examiner should require the subject to visually fixate
on two separate objects, e.g. the examiner’s finger and a hatpin, which are displaced first horizontally and then vertically (up and down), but
always within the subject’s visual field. The subject is then asked to look at each object alternately.
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A history of drop attacks or loss of posture associated
with emotional stimuli (e.g. laughing or crying) should
raise the suspicion for gelastic cataplexy. This sign may
be missed in children, as falls due to cataplexy may be
often misinterpreted as secondary to cerebellar ataxia
[1,39]. Gelastic cataplexy, characterised by a normal elec-
troencephalogram (EEG), must be differentiated from
gelastic seizures, which exhibit clinical features of epilepsy
and usually abnormal EEG. As gelastic cataplexy can be
part of the narcoleptic tetrad, which includes cataplexy,
narcolepsy, sleep paralysis and hypnagogic hallucinations,
it is important to exclude narcolepsy, which is not ob-
served in patients with NP-C.
Dystonia
Dystonia is a neurological movement disorder characterised
by excessive involuntary muscle contraction as a result of
pathology in the basal ganglia and, to a lesser extent, the
cerebellum [35,40]. This symptom is very common and, if
present in patients with NP-C, occurs more frequently in
the adolescent/adult onset form than in the juvenile form
[2,39] and is a moderate indicator of the disease [18].
In NP-C, dystonia rarely presents in isolation but usually
with ataxia, a combination highly specific for NP-C [17].
Occasionally, dystonia may present in isolation of ataxia,
which can lead to misdiagnosis as genetic forms of
primary dystonia, for example DYT1 and DYT6, In NP-C,
dystonia affects the extremities and the face. During later
stages of the disease, dystonia may also involve the neck
and trunk, and as illness progresses it can also affect gait
[41]. Typical dystonic features in NP-C include focal hand
dystonia with wrist flexion, a forced (subtle) smile when
speaking, resulting from dystonia of the jaw musculature
and wrinkles on the forehead. Dystonia tends to worsen
during intercurrent illnesses. Differential diagnosis of
dystonia in inborn errors of metabolism include respira-
tory chain disorders, pyruvate dehydrogenase deficiency,
glucose transporter 1 deficiency, vitamin E deficiency, or-
ganic acidaemia, urea cycle disorders, homocystinuria and
Wilson disease. Genetic forms of primary dystonia, such
as DYT1 and DYT6, are not strictly neurodegenerative.
Dysarthria/dysphagia
Dysarthria results in slurred and irregular speech with
impaired pronunciation, due to a lack of coordination of
the motor-speech system [42]. It results from a combin-
ation of ataxia and dystonia and involves pathologies in
the cerebellum and basal ganglia. Dysarthria is a moderate
indicator of NP-C [18] which, in combination with other
symptoms, increases the diagnostic likelihood of NP-C.
Dysphagia, or difficulty in swallowing, is associated with
dysfunction not only in the brainstem (affecting motor
and sensory functions of swallowing), but also in cortical
areas in the frontal lobe (responsible for swallowing initi-
ation as well as management and retention of safe swal-
lowing strategies) [43,44]. This common symptom of
NP-C may appear early or later in the disease course [1].
It is a moderate indicator of NP-C and its combination
with other symptoms is specific to the disease [18].
Dysphagia represents a major problem as it correlates
with aspiration pneumonia, one the most common
causes of death of NP-C [45,46]. Swallowing function
can be assessed by standardised swallowing assessments
of different substances, and via investigations such as
video fluoroscopy and fiberoptic endoscopic evaluation
of swallowing [47-49].
Hypotonia
Hypotonia, the first neurological signs of NP-C appearing
in the second year of life, is a non-specific indicator of
the disease, but early onset of hypotonia around or before
the first birthday is associated with the more progressive
infantile type of NP-C [18]. In toddlers, clumsiness results
from a combination of hypotonia, beginning of ataxia and
abnormal eye movements, which lead to stumbling over
obstacles. In school children clumsiness is usually related
to ataxia and may manifest as the deterioration of
handwriting. This deterioration is related to the onset
of dysmetria, a lack of movement coordination that
can be detected using the Archimedes spiral test.
Delayed developmental milestones
Delays in the developmental milestones are an ancillary
indicator of NP-C [18]. These include motor delays (e.g.
slow movements while walking and transferring objects,
clumsiness, poor head control), speech delay, vision/ocular-
motor developmental delay, and social delay (e.g. interactive
play). When associated with other manifestations such as
isolated splenomegaly without hepatomegaly and VSGP,
this sign becomes specific to NP-C. Virtually all children
with NP-C exhibiting developmental delays have a history
of splenomegaly. In practice, the range and extent of
developmental delay can vary widely between patients,
but can be very useful for early diagnosis in infant and
juvenile patients. The majority of infants will typically
fail to reach some, or all, of the following developmental
milestones, in the following chronological order: delays
in picking up and transferring small objects; lack of visual
attention; delayed walking; frequent falls and a tendency
cruise/hold onto parents/solid objects to aid balance. A
common feature in juveniles is a delay in language, until
3–4 years old. However, this sign is not specific to NP-C
as speech delay may have many causes, and other signs
and symptoms should therefore be checked.
Seizures
Seizures are not specific to NP-C and are considered an
ancillary indicator of the disease [18]. In NP-C, seizures can
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be partial/focal, or generalised, myoclonic or tonic-clonic,
and can vary substantially in frequency and intensity [1]. In
the differential diagnosis process, it is important to exclude
other disease involving seizures, e.g. myoclonic epilepsy or
mitochondrial disease.
Hearing loss
High frequency sensorineural hearing loss has been
reported in NP-C and can be light or severe [2,5]. It
affects about 20% of the patients and appears to be
more frequent in adults. Hearing ability can be tested
by audiograms or auditory brainstem responses.
It is believed that cholesterol, whose trafficking is
impaired in NP-C, plays a key role in auditory physiology
[50,51]. Animal studies have shown that the cholesterol-
chelating agent 2-hydroxypropyl-β-cyclodextrin, a promis-
ing experimental therapy for NP-C, may have deleterious
effects on hearing impairment [52,53], emphasising
the need for auditory testing in patients receiving this
treatment.
Psychiatric symptoms in NP-C
Cognitive decline
Progressive cognitive decline affects all patients with
NP-C and is a strong indicator of the disease [18]. In
combination with VSGP, cognitive decline is strongly
suggestive of NP-C.
In adult forms of NP-C, the typical profile is cha-
racterised by initial deficits in executive functioning,
followed by memory impairment and cognitive slowing.
In adult patients initial changes may be subtle. Executive
impairment includes very early disinhibition, perseveration
(i.e. inflexibility in thinking and inability to shift set), poor
judgement, lack of insight, impaired ability for abstraction,
attentional deficits, and cognitive slowing. Disinhibition is
often the earliest sign, detected neuropsychologically by
tools such as the Stroop colour-word test [28]. However,
memory impairment can also manifest as an early feature.
Cognitive impairment in children manifests as a delay
in normal cognitive development, or mental retard-
ation. It is common that children reach a certain stage
of development, stop progressing, and start showing
cognitive decline associated with functional loss.
Attention-deficit hyperactivity disorder may be present
in childhood as a precursor to adolescent or adult
development of NP-C.
Memory deficits, including impaired formation of new
memories and disorientation, reflect hippocampal ab-
normalities [54,55]. Cognitive slowing may be due to
changes in white matter causing disconnection of frontal-
subcortical circuitry [56]. In addition, direct striatal
pathology causes cognitive slowing through disruption
of frontostriatal loops [57].
Cognitive impairment is commonly screened for by
performing a Mini-Mental State Evaluation [58]. Al-
though not sensitive in early stages of NP-C, it is useful
for assessing cognitive function in patients with moder-
ately severe NP-C in more advanced stages. Other trad-
itional neuropsychological tests for global cognition and
memory include the Wechsler Adult Intelligence Scale
(WAIS) [59] and the Wechsler Memory Scale (WMS).
Tests for executive dysfunction include the trail-making
test and the Controlled Oral Word Association test
[60]. Moreover, memory deficits can be assessed, for ex-
ample, by the Rey Auditory Verbal Learning Test
(RAVTL) [61].
In children, cognitive impairment may be monitored
using the Bayley Scales for Infant Development [62],
Vineland Adaptive Behaviour Scales [63], the Wechsler
Intelligence Scale for Children [64], the Denver Develop-
mental Screening Test [65] and the Griffiths Mental
Development Scale [66].
NP-C should be differentiated from Alzheimer’s disease
(AD), also characterised by cognitive decline and short-
term memory loss. Cognitive impairment in NP-C is
characterised by a more pronounced prefrontal involve-
ment, as opposed to the more generalised dementia and
different degree of cognitive slowing observed in patients
with AD. As a result, patients with NP-C mostly exhibit
deficits in executive function and disinhibition. Whilst
executive deficits in adult patients in NP-C are similar to
those observed in patients with frontotemporal dementia
[67], the presence of VSGP and motor signs such as ataxia
and dystonia allows readily differentiating the two diseases.
Psychosis
Psychosis is characterised by hallucinations, delusions and/
or thought disorder and is a moderate indicator of NP-C
[18]. In NP-C, psychotic symptoms typically present in
adolescence or early adulthood, may be treatment resistant
and sensitive to neuroleptic side effects (particularly dys-
tonia), and may be associated with secondary signs (visual
hallucinations, catatonia and fluctuating symptoms) [68].
Disruptive or aggressive behaviour in adolescence
and childhood
Disruptive or aggressive behaviour in adolescence and
childhood is an ancillary indicator of NP-C [18]. In
pubescent patients, it may present in addition to cogni-
tive impairment and behavioural disinhibition.
Diagnosis and diagnostic methods
As described earlier, NP-C presents in a highly heteroge-
neous manner, sometimes with atypical phenotypes, which
makes the disease difficult to detect.
An NP-C Suspicion Index (SI) tool was recently devel-
oped to aid clinicians identify patients with suspicion of
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NP-C, for whom other common diseases have been ruled
out [18]. This highly specific, sensitive, easy-to-use and
reliable tool provides information about symptomatology
and presentation patterns in NP-C [18].
The diagnostic process includes recording a full medical
history and a comprehensive clinical and neurological
examination to detect characteristic signs and symptoms,
followed by a differential diagnostic procedure to exclude
other possible causes and, finally, confirmation of NP-C
diagnosis by biochemical (filipin staining) and genetic test-
ing [1,69-71]. As part of genetic counselling, heterozygous
carriers should always undergo genetic testing in order to
reliably determine their genetic status, which is useful for
family planning implications [1]. Oxysterols (cholesterol
oxidation products) have recently been shown to be
significantly elevated in the plasma of patients with
NP-C1 [72,73], thus bearing the potential for being
used as biomarkers for NP-C. Measurement of plasma
oxysterol levels is recommended as a supplementary
test for cases with unclear NP-C genetic mutations and
biochemical phenotypes [1].
Disease management and treatment
Detailed guidelines have been recently published on disease
management including treatment [1]. In the absence of
a curative treatment, improving or maintaining patients’
quality of life and their neurological and mental functions
is considered the best possible reasonable goal. Optimal
disease management should rely on a multidisciplinary
treatment approach, combining symptomatic treatment,
close community support and disease-specific therapy.
To date, miglustat is the only disease-specific approved
therapy for the treatment of progressive neurological
manifestations in paediatric and adult patients with
NP-C [7]. Miglustat has been shown to improve or stabilise
key parameters of neurological disease progression in
children, and in juvenile and adult patients, both in clinical
trials and in clinical practice settings [47,49,74-79].
In order to stabilise or slow the progression of irre-
versible neurological damage, disease-specific therapy
with miglustat should be initiated at the earliest signs
of neurological manifestations [1].
Prognosis
NP-C is a progressive, irreversible and chronically debili-
tating disease leading to premature death, usually between
the ages of 10 and 25 years according to previous studies
[70]. However, this figure may no longer be valid as more
late-onset patients are now diagnosed in adulthood. Prog-
nosis largely correlates with age at onset of neurological
signs, whereby early-onset forms progress faster [1,2].
Dysphagia has been identified as a major risk factor for
mortality in patients with NP-C [46]. In fact, impaired
swallowing is associated with aspiration pneumonia, the
most common cause of death in neurodegenerative disease
including NP-C [45,46,80]. Improving swallowing function
may therefore help increase patients’ life expectancy.
Unresolved questions and future perspectives
Despite increasing research in the field, open questions
remain regarding the exact function of NPC1 and NPC2
proteins, as well as the precise role of sphingosine and
other lipids in the pathogenesis of NP-C [14]. As such,
further investigations are required to elucidate the bio-
chemical and cellular mechanisms leading to the disease,
in order to design new targeted therapies. Moreover, this
may help understand the connection between a traffic
lipid disorder and the various neurological phenotypes
observed in patients.
The lack of a single, definitive diagnostic test for all
populations means that NP-C remains largely under- or
misdiagnosed. Currently available screening and diagnos-
tic techniques are not straightforward and may contribute
to delays in diagnosis. The advent of faster and cheaper
genetic tests such as Next-Generation Sequencing, as well
as the potential use of plasma oxysterols as biomarkers of
NP-C [1,72,73], will likely have a great impact on future
screening and diagnostic strategies for NP-C and other
rare diseases. Establishment of a test to implement
oxysterols for their potential use as screening and diag-
nostic biomarkers is currently under development. Fur-
thermore, preliminary data indicate that levels of certain
oxysterol species correlate with disease severity in patients
with NP-C1 [73]. However, further data are required to
determine whether oxysterols may be used as biomarkers
for monitoring disease progression.
Walterfang et al. have recently shown that patients
with NP-C exhibit alterations in brain morphology
[35,81-83]. Preliminary data suggest that miglustat can
maintain brain volume in treated patients compared
with untreated control subjects. However, further evi-
dence is required to establish whether miglustat has an
effect on brain morphology and whether magnetic res-
onance imaging measures can be used to monitor dis-
ease progression (Walterfang, unpublished data).
Conclusions
Detection of NP-C remains challenging, due to the highly
heterogeneous presentation of the disease, with manifesta-
tions occurring along a continuum. While individual signs
and symptoms may not be specific to NP-C, their specific
combinations can be an important indication of the dis-
ease [18]. Therefore, single findings are often insufficient
and further investigations to identify any other symptom
should always be performed when a diagnosis is lacking.
Correct assessment of different symptoms is crucial to
identifying the disease. A combination of splenomegaly,
VSGP and cognitive impairment, together with other,
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non-specific visceral, neurological or psychiatric mani-
festations, is highly predictive of NP-C. Tools such as
the NP-C Suspicion Index tool may offer considerable
help in the diagnostic process [18].
Minimising the delay in diagnosis is crucial for prompt
initiation of disease-specific therapy in order to slow
progression of neurological disease and to improve patient
care and treatment outcomes. This expert-based clinical
description of NP-C signs and symptoms is a further
step towards raising disease awareness and improving
early detection, a goal for which the medical community
strives in the near future.
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